Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pelareorep in 3rd line HR+/HER2 negative breast cancer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 01, 2024 1:06pm

87 Views

Post# 36248578

RE:Pelareorep in 3rd line HR+/HER2 negative breast cancer

September 30, 2024 - Roche/Genentech is beginning to turn on its acquistion tap with an $850 million upfront for Regor Pharmaceuticals’ Phase 1 portfolio of CDK inhibitors, taking ownership of a breast cancer candidate (RGT-419B) that has shown signs of single-agent efficacy in patients failed by existing options.

ONCY is demonstrating pelareorep's single agent effectiveness in breast cancer and is synergistic with small molecules suich as CDK inhibitors.

https://www.fiercebiotech.com/biotech/genentech-inks-850m-upfront-deal-regors-cdk-inhibitors-furthering-breast-cancer-expansion

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals